In addition to her role as Chief Executive Officer and member of the Board of Directors, Veronica is also responsible for the clinical development programs and regulatory affairs at LimmaTech. Most recently, she was Executive Director at GlycoVaxyn. She joined GlycoVaxyn as head of the clinical and regulatory affairs department in 2009. Before joining GlycoVaxyn, she held leading roles focused on clinical R&D and international regulatory affairs in medical technology and biotechnology companies, including EndoArt SA and Allergan Inc. Veronica holds an engineering degree from the ETH Zürich and a PhD in life sciences in the field of cardiovascular biomedical engineering from the Swiss Federal Institute of Technology in Lausanne.
· The development plan for a Shigella vaccine demonstrated in PhI and a PhIIB human challenge study
· A regulatory tool for licensing